Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28529403
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Proc+SPIE+Int+Soc+Opt+Eng
2016 ; 9708
(ä): ä Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Prostate cancer characterization by optical contrast enhanced photoacoustics
#MMPMID28529403
Xu G
; Qin M
; Mukundan A
; Siddiqui J
; Takada M
; Vilar-Saavedra P
; Tomlins SA
; Kopelman R
; Wang X
Proc SPIE Int Soc Opt Eng
2016[Feb]; 9708
(ä): ä PMID28529403
show ga
During the past decades, prostate cancer (PCa), with an annual incident rate much
higher than any other cancer, is the most commonly diagnosed cancer in American
men. PCa has a relatively low progression rate yet the survival percentage
decreases dramatically once the cancer has metastasized. Identifying aggressive
from indolent PCa to prevent metastasis and death is critical to improve outcomes
for patients with PCa. Standard procedure for assessing the aggressiveness of PCa
involves the removal of tumor tissues by transrectal (TR) ultrasound (US) guided
needle biopsy. The microscopic architecture of the biopsied tissue is visualized
by histological or immunohistochemical staining procedures. The heterogeneity of
the microscopic architecture is characterized by a Gleason score, a quantitative
description of the aggressiveness of PCa. Due to the inability to identify the
cancer cells, most noninvasive imaging modalities can only provide diagnosis of
PCa at limited accuracy. This study investigates the feasibility of identifying
PCa tumors and characterizing the aggressiveness of PCa by photoacoustic imaging
assisted by cancer targeting polyacrylamide (PAA) nanoparticles (NPs). PAA is a
biocompatible material used in clinics for the past 20 years. PAA NPs can protect
capsulated optical contrast agents from interference by enzymes and enable
prolonged systematic circulation in the living biological environment. The cancer
targeting mechanism is achieved by conjugating the NPs to F3 peptides, which
trace nucleolin overexpressed on the surface of cancer cells. Preliminary studies
have shown that the NPs are capable of staining the PCa cells in vivo.